Trial Outcomes & Findings for PREVENT HPV-Related Cancers - BootCamp Translation (NCT NCT06290206)
NCT ID: NCT06290206
Last Updated: 2025-05-18
Results Overview
This outcome measure will report the number of participants who participant in the BCT English sessions and number of participants who participant in the BCT Spanish sessions. BCT is a community-based research approach to develop and evaluate messaging for health related issues. This study will employ BCT to determine the frequency and content of HPV messaging for future research.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
18 participants
Primary outcome timeframe
1 day after study enrollment
Results posted on
2025-05-18
Participant Flow
Participant milestones
| Measure |
English Language Session and Messaging
The in-person or live Zoom presentation in English will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).
Participants in the English-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period.
|
Spanish Language Session and Messaging
The in-person or live Zoom presentation in Spanish will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).
Participants in the Spanish-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period.
|
|---|---|---|
|
Overall Study
STARTED
|
8
|
10
|
|
Overall Study
COMPLETED
|
8
|
10
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
PREVENT HPV-Related Cancers - BootCamp Translation
Baseline characteristics by cohort
| Measure |
English Language Session and Messaging
n=8 Participants
The in-person or live Zoom presentation in English will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).
Participants in the English-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period.
|
Spanish Language Session and Messaging
n=10 Participants
The in-person or live Zoom presentation in Spanish will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).
Participants in the Spanish-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period.
|
Total
n=18 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
8 Participants
n=93 Participants
|
10 Participants
n=4 Participants
|
18 Participants
n=27 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Age, Continuous
|
43.13 years
STANDARD_DEVIATION 7.43 • n=93 Participants
|
40.50 years
STANDARD_DEVIATION 7.06 • n=4 Participants
|
41.67 years
STANDARD_DEVIATION 7.14 • n=27 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=93 Participants
|
10 Participants
n=4 Participants
|
18 Participants
n=27 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
3 Participants
n=93 Participants
|
9 Participants
n=4 Participants
|
12 Participants
n=27 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
5 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
6 Participants
n=27 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=27 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=27 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
2 Participants
n=27 Participants
|
|
Race (NIH/OMB)
White
|
4 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
5 Participants
n=27 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=27 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=93 Participants
|
8 Participants
n=4 Participants
|
8 Participants
n=27 Participants
|
|
Region of Enrollment
United States
|
8 participants
n=93 Participants
|
10 participants
n=4 Participants
|
18 participants
n=27 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(ren) This Year
Extremely likely
|
3 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
3 Participants
n=27 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(ren) This Year
Likely
|
1 Participants
n=93 Participants
|
3 Participants
n=4 Participants
|
4 Participants
n=27 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(ren) This Year
Neutral
|
2 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
3 Participants
n=27 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(ren) This Year
Unlikely
|
1 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=27 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(ren) This Year
Extremely unlikely
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(ren) This Year
My child(ren) has already received the HPV vaccine
|
1 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=27 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(ren) This Year
Prefer not to answer
|
0 Participants
n=93 Participants
|
4 Participants
n=4 Participants
|
4 Participants
n=27 Participants
|
PRIMARY outcome
Timeframe: 1 day after study enrollmentThis outcome measure will report the number of participants who participant in the BCT English sessions and number of participants who participant in the BCT Spanish sessions. BCT is a community-based research approach to develop and evaluate messaging for health related issues. This study will employ BCT to determine the frequency and content of HPV messaging for future research.
Outcome measures
| Measure |
English Language Session and Messaging
n=8 Participants
The in-person or live Zoom presentation in English will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).
Participants in the English-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period.
|
Spanish Language Session and Messaging
n=10 Participants
The in-person or live Zoom presentation in Spanish will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).
Participants in the Spanish-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period.
|
|---|---|---|
|
Number of Parents Participating in BCT
|
8 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: After the in-person session (1 day)Participants will be surveyed before and after the in-person session to assess learning outcomes. This outcome measure is a single-item self-report of the intention of parents to get the HPV vaccination for their children this year. A low score (Minimum: 1 Extremely Unlikely) is an unfavorable outcome and a high score (Maximum: 5 Extremely Likely) is a favorable outcome. This outcome measure will report the number of patients per response for the BCT English sessions and the BCT Spanish sessions.
Outcome measures
| Measure |
English Language Session and Messaging
n=8 Participants
The in-person or live Zoom presentation in English will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).
Participants in the English-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period.
|
Spanish Language Session and Messaging
n=10 Participants
The in-person or live Zoom presentation in Spanish will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).
Participants in the Spanish-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period.
|
|---|---|---|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(Ren) This Year
Extremely likely
|
6 Participants
|
1 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(Ren) This Year
Likely
|
1 Participants
|
5 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(Ren) This Year
Neutral
|
0 Participants
|
1 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(Ren) This Year
Unlikely
|
0 Participants
|
0 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(Ren) This Year
Extremely unlikely
|
0 Participants
|
2 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(Ren) This Year
My child(ren) has already received the HPV vaccine
|
1 Participants
|
1 Participants
|
|
Likelihood of Parents to Get the HPV Vaccination for Their Child(Ren) This Year
Prefer not to answer
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: After the in-person session (1 day)Population: One participant in the English Language Session did not answer this item.
Participants will be surveyed before and after the in-person session to assess learning outcomes. This outcome measure is a single-item self-report of the participants satisfaction with the BCT session. A low score (Minimum: 1 Not at all satisfied) is an unfavorable outcome and a high score (Maximum: 10 Extremely satisfied) is a favorable outcome. This outcome measure will report the mean score of participants for the BCT English sessions and the BCT Spanish sessions.
Outcome measures
| Measure |
English Language Session and Messaging
n=7 Participants
The in-person or live Zoom presentation in English will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).
Participants in the English-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period.
|
Spanish Language Session and Messaging
n=10 Participants
The in-person or live Zoom presentation in Spanish will consist of an expert presentation about the research on the safety and effectiveness of the HPV vaccine and social norms about vaccination. In this session, participants will receive up-to-date evidence on effective messaging by clinicians (e.g., using presumptive statements, bundling HPV vaccine recommendations with recommendations for other vaccines) in addition to novel formats for educational messages (e.g., digital videos, narratives).
Participants in the Spanish-language text message group will provide iterative feedback to the research team on HPV vaccination messages over a 3-month period.
|
|---|---|---|
|
Satisfaction With BCT Session
|
9.71 units on a scale
Standard Deviation 0.49
|
9.10 units on a scale
Standard Deviation 1.29
|
Adverse Events
English Language Session and Messaging
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Spanish Language Session and Messaging
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place